Community Health Center Drug Pricing Protection Act
Summary
HR7391 is an early-stage bill mandating upfront 340B ceiling pricing for FQHCs. It eliminates rebate reconciliation, structurally benefiting PBMs and managed care organizations handling safety-net populations. The bill has 49 cosponsors but remains in committee with no appropriation attached. Modest structural win for Optum Rx ($UNH) but negligible near-term financial impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7391 is an early-stage, zero-dollar authorization bill with no appropriation attached — procedural, not fiscal.
- 2.The bill structurally simplifies pricing for PBMs serving FQHCs, but the financial impact on any public company is marginal given the small proportion of 340B safety-net claims in total PBM revenue.
- 3.No publicly traded manufacturer is directly harmed; the timing change (upfront vs rebate) does not alter total revenue from 340B sales.
- 4.Recent stock rallies in $CI and $HUM are attributable to managed care sector momentum and MA rate cycles, not this bill.
Market Implications
Near-term market impact is negligible. The bill is in committee with no legislative velocity. Active traders should not adjust positions based on HR7391. For long-term positioning, $UNH's Optum Rx has a marginal structural benefit if the bill passes, but the upside is immaterial to UNH's $400B+ revenue base. Broader 340B reform (which this bill does NOT address — it only changes timing) could be a larger catalyst, but that is not this legislation.
Full Analysis
What Happened: On February 5, 2026, Rep. Bergman (R-MI) introduced HR7391, the Community Health Center Drug Pricing Protection Act. The bill has been referred to the House Energy and Commerce Committee. It currently has 49 cosponsors (1 sponsor + 49 cosponsors per enrichment data), a bipartisan group including members like Mr. Auchincloss (D-MA) and Ms. Norton (D-DC). The bill is in early stage (referred to committee, no hearings or markup reported).
The Money Trail: HR7391 authorizes zero dollars. It is a regulatory mandate, not a spending bill. The mechanism amends Section 340B(a) of the Public Health Service Act to require that manufacturers sell covered outpatient drugs to FQHCs at no more than the 340B ceiling price at the point of purchase, and explicitly prohibits arrangements requiring later reconciliation by rebate. No appropriation is needed; it changes pricing conduct, not government expenditure.
Structural Winners and Losers: The primary beneficiaries are PBMs and managed care organizations that administer pharmacy benefits for safety-net populations. Optum Rx is the clearest public company exposed, as one of the top 3 PBMs. Cigna ($CI, Express Scripts) and Humana ($HUM) also have PBM operations, but the direct link is weaker — these companies' PBM arms serve broader populations, and safety-net 340B claims represent a small fraction. The bill removes administrative drag on a small segment. No publicly traded company is a clear loser from this specific provision, as manufacturers (e.g., $LLY, $MRK, $PFE) already must offer 340B pricing to covered entities; this merely changes the timing mechanism. Broader implications for the 340B program debate are neutral-to-slightly-negative for manufacturers over the long term if this is a wedge for more 340B expansion, but that is speculative.
Market Data Analysis: Per REAL MARKET DATA, $CI trades at $291.99 (52-week range $239.51–$350), up 5.93% in 7 days and 9.46% in 30 days. $HUM is at $239.86 (52-week $163.11–$315.35), surging 11.44% weekly and 38.34% monthly. These runs appear tied to broader managed care earnings momentum and MA rate news, not to HR7391 (introduced Feb 5, no price reaction detectable). The bill's early stage and zero dollar amount mean the price action is unrelated to this legislation.
Timeline: The bill must pass House Energy and Commerce Committee, then the full House, then identical Senate bill, then President's signature. No Senate companion has been identified. No hearings scheduled. Given referral in early February 2026 and no further action by late April, the legislative velocity is very slow. Passage in the 119th Congress is uncertain.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
American Innovation and R&D Competitiveness Act of 2025
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Association Health Plans Act
Medicare for All Act
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Veterans’ ACCESS Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.